Alembic Share Price

Alembic Limited is one of the Indias most experienced manufactures of bulk drugs and pharmaceuticals formulation in human and animal healthcare. The Company operates primarily in the manufacture of Bulk Drugs and Real Estate Business. The company manufacture pharmaceuticals and chemicals, bulk drugs (penicillin and other antibiotics) and formulations. It works manufacturing facilities at Vadodara in Gujarat and Solan in Himachal Pradesh.Alembic Limited was incorporated in year 1907 with the name Alembic Chemical Works Company Limited in Vadodara to manufacture tinctures and alcohol. The name of the Company was changed to Alembic Limited in August, 1999. The Company started to manufacture cough syrup, vitamins, tonics and sulphur durgs in 1940. In 1961, it inaugurated the Pencillin Palnt. In 1968, it started to manufacture Streptomycin.In the 1971, they manufactured Erythromycin using expertise from Eli Lilly, USA and in the year 1972, they launched Althrocin, a brand of Erythromycin. In year 1997, Althrocin become top selling brand in India. In the year 2001, they started to manufacture Cephalosporin C. In June 2001, the company formed a wholly owned subsidiary company named Alembic Europe Pvt Ltd in UK.In the year 2005, the company has launched ZERO, a new generation, no calories, Sucralose Based Sugar Substitute which gave entry for the company into the highgrowth lifestyle OTC product segment. In May 2005, the generic alliances and API division were merged to form an independent SBU.The company has set up a formulation manufacturing facility at Baddi in Himachal Pradesh with a production capacity 900 million tablets and 600 million liquid oral bottles annually. During the year 200506, the company has increased the installed capacity of Tablets Capsules and Oral Preparation Ointments by 595 Million Nos and 720 MT respectively.During the year 200506, the company acquired API Plant at Karakhadi in Vadodara. In the year 2007, the company acquired the NonOncology Business of Dabur Pharma Ltd. Also in the same year, they entered into a licensing agreement for its Novel Drug Delivery Platform for Keppra XR with UCB Belgium. During the year 200708, the company acquired the API manufacturing facility of Nirayu Pvt Ltd at Panelav near Vododara.The Company formed a wholly owned subsidiary viz. Alembic Global Holding SA in Neuchatel, Switzerland in 2009. The Pharmaceutical Undertaking of the Company demerged and the same got transferred to Alembic Pharmaceuticals Limited with effect from Appointed date i.e. 1st April, 2010. The maiden real estate project Samsara was completed in 2014. The Company launched second real estate project, VEDA in 201516. It further launched two APIs in 2017. During year 201718, Alembic City Limited (formerly known as Alembic Exports Limited) became whollyowned subsidiary of the Company.During 201819, the Composite Scheme of Arrangement comprising of transfer and vesting of the Identified Real Estate Undertaking of the Company into Shreno Limited and transfer and vesting of Engineering Division and Investment Division of Shreno Limited into Nirayu Private Limited and their respective shareholders with effect from November 1, 2018 was sanctioned by the Honble National Company Law Tribunal, Ahmedabad Bench (NCLT) vide its order dated 26th July, 2019. Accordingly, Scheme was made effective from 26th July, 2019.The Company launched a residential project VEDA II during 2020. In FY 2025, VEDAII, one of the Companys gated community project has been completed in FY 2025. The Companys upscale premium residential projects, Townhouse24 also achieved 100% sales during the year. Other premium projects like The Villas and The Gardens witnessed decent demand. The Company also launched another housing project with 3BHK and 4BHK configurations called The Park Crescent..

For the full year FY2026–2027, revenue reached ₹312.96 crore and profit touched at ₹125.93 crore.